Exemplis Discimus 2010, 154(4):297-306

Maecenas sed eros ut augue semper scelerisque.

Jann Dimmiasa, Worma Abermiacib, Anya Sholc, Chaz Ke'Sahndhrana
a Clinic of Operation Room Technology, Faculty Hospital of Gordin Reach, Republic of Sullust
b 2nd Clinic of Cardiology, Maramere Faculty Hospital, Taanab Republic
c Department of Health Care Management, Faculty Hospital of Nilgaard, Boz Pity Republic

Background: Quisque sed tellus in enim malesuada viverra. Mauris lectus est, lacinia eu, euismod ac, cursus quis, mauris. Nam nisl leo, venenatis eu, ornare ac, viverra id, lacus. Vestibulum at nunc in urna consectetuer commodo. Proin felis erat, tristique id, ornare vitae, auctor quis, purus. Praesent mi risus, aliquam at, venenatis ac, bibendum at, arcu. Nullam orci leo, porttitor non, rhoncus nec, congue porttitor, magna. Nulla et turpis in sapien lacinia porttitor.

Methods and Results: Nullam lectus sem, luctus a, luctus eget, rhoncus sed, nibh. Vivamus et sapien nec metus faucibus luctus. Aenean lectus metus, tincidunt ullamcorper, auctor vitae, dapibus nec, est.. Aliquam lectus nibh, vehicula non, congue ut, malesuada ac, elit. Praesent id diam eu turpis tincidunt suscipit. Maecenas vel tortor vel nulla molestie faucibus. Nullam lectus sem, luctus a, luctus eget, rhoncus sed, nibh. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Conclusions: Nam urna eros, suscipit eu, commodo vel, sollicitudin vel, nisl. Vivamus placerat elit ac sem facilisis lobortis. Proin ligula lacus, sollicitudin in, euismod quis, elementum vitae, turpis. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Vivamus tellus lacus, faucibus ac, vehicula vel, porttitor vitae, mauris. Curabitur risus arcu, fermentum eu, consectetuer ut, tempus nec, lorem. Mauris lectus est, lacinia eu, euismod ac, cursus quis, mauris. Mauris quis velit nec massa convallis eleifend.

Kľúčové slová: Mauris et dui, Nulla facilisi, Donec nec lacus, Suspendisse potenti, Sed vestibulum lacus, Etiam lacus

Vložený: May 24, 2010; Přijatý: November 12, 2010; Uverejnené: December 1, 2010 

Zobraziť celý článok

Referencie

  1. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentlow BD, Rolles K. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978;2:1323 1327. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  2. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989;2:10001004. Prejsť k pôvodnému zdroju...
  3. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:27152729. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  4. Andreoni KA, Brayman KL, Guidinger MK, Sommers CM, Sung RS. Kidney and pancreas transplantation in the United States, 19962005. Am J Transplant 2007;7:13591375. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  5. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine A and FK-506. Immunol Today 1992;12:136142. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  6. Liu EH, Siegel RM, Harlan DM, OShea JJ. T cell-directed therapies: Lessons learned and future prospects. Nat Immunol 2007;8:2530. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  7. Chapman JR, Nankivell BJ. Nephrotoxicity of ciclosporin A: shortterm gain, long-term pain? Nephrol Dial Transplant 2006;21:2060 2063. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  8. Naesens M, Lerut E, Damme BV, Vanrenterghem Y, Kuypers DR. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant 2007;7:2114 2123. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  9. Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993;91:21442149. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  10. Lamas S. Cellular mechanisms of vascular injury mediated by calcineurin inhibitors. Kidney Int 2005;68:898907. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  11. Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: A role of aldosterone. Am J Physiol Renal Physiol 2007;293:F2F9. Prejsť k pôvodnému zdroju...
  12. Wissmann C, Frey FJ, Ferrari P, Uehlinger DE. Acute cyclosporineinduced nephrotoxicity in renal transplant recipients: The role of the transplanted kidney. J Am Soc Nephrol 1996;7:26772681.
  13. Kurtz A, Della BR, Kuhn K. Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells. Kidney Int 1988;33:947953. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  14. Ruster C, Wolf G. Renin-angiotensin-aldosterone systém and progression of renal disease. J Am Soc Nephrol 2006;17:29852991. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  15. Iijima K, Hamahira K, Kobayashi A, Nakamura H, Yoshikawa N. Immunohistochemical analysis of renin aktivity in chronic cyclosporine nephropathy in childhood neohrotiv syndrome. J Am Soc Nephrol 2000;11:22652271.
  16. Zhong Z, Arteel GE, Connor HD, Yin M, Frankenberg MV, Stachlewitz RF, Raleigh JA, Mason RP, Thurman RG. Cyclosporin A increases hypoxia and free radical production in rat kidneys: Prevention by dietary glycine. Am J Physiol 1988;275:F595F604.
  17. Diederich D, Skopec J, Diederich A, Dai FX. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension 1994;23:957961. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  18. Navarro-Antolin J, Lopez-Munoz MJ, Klatt P, Soria J, Michel T, Lamas S. Formation of peroxynitrite in vascular endothelial cells exposed to cyclosporine A. FASEB J 2001;15:12911293. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  19. Sugimoto T, Haneda M, Sawano H, Isshiki K, Maeda S, Koya D, Inoki K, Yasuda H, Kashiwagi A, Kikkawa R. Endothelin-1 induces cyclooxygenase-2 expression via nuclear factor of activated T-cell transcription factor in glomerular mesangial cells. J Am Soc Nephrol 2001;12:13591368.
  20. Hocherl K, Dreher F, Vitzthum H, Kohler J, Kurtz A. Cyclosporine A suppresses cyclooxygenase-2 expression in the rat kidney. J Am Soc Nephrol 2002;13:24272436. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  21. Mihatsch MJ, Thiel G, Basler V, Ryffel B, Landmann J, von Overbeck J, Zollinger HU. Morphological patterns in cyclosporinetreated renal transplant recipients. Transplant Proc 1985;17:101 116. Prejsť na PubMed...
  22. Morozumi K, Takeda A, Uchida K, Mihatsch MJ. Cyclosporine nephrotoxicity: how does it affect renal allograft function and transplant morphology? Transpl Proc 2004;36:S251S256. Prejsť k pôvodnému zdroju...
  23. Pallet N, Rabant M, Xu-Dubois YC, Lecorre D, Mucchielli MH, Imbeaud S, Agier N, Hertig A, Thervet E, Legendre C, Beaune P, Anglicheau D. Response of human renal tubular cells to cyclosporine and sirolimus: a toxicogenomic study. Toxicol Appl Pharmacol 2008;229:184196. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  24. Bouvier N, Flinois JP, Gilleron J, Sauvage FL, Legendre C, Beaune P, Thervet E, Anglicheau D, Pallet N. Cyclosporine triggers endoplasmic reticulum stress in endothelial cells: a role for endothelial phenotypic changes and death. Am J Physiol Renal Physiol 2009;296:F160F169. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  25. Pallet N, Bouvier N, Bendjallabah A, Rabant M, Flinois JP, Hertig A, Legendre C, Beaune P, Thervet E, Anglicheau D. Cyclosporineinduced endoplasmic reticulum stress triggers tubular phenotypic changes and death. Am J Transplant 2008;8:22832296. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  26. Han SW, Li C, Ahn KO, Lim SW, Song HG, Jang YS, Cho YM, Jang YM, Ghee JY, Kim JY, Kim SH, Kim J, Kwon OJ, Yang CW. Prolonged endoplasmic reticulum stress induces apoptotic cell death in an experimental model of chronic cyclosporine nephropathy. Am J Nephrol 2008;28:707714. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  27. Du S, Hiramatsu N, Hayakawa K, Kasai A, Okamura M, Huang T, Yao J, Takeda M, Araki I, Sawada N, Paton AW, Paton JC, Kitamura M. Suppression of NF-B by cyclosporine A and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response. J Immunol 2009;182:72017211. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  28. Naesens M, Kambham N, Concepcion W, Salvatierra O, Jr., Sarwal M. The evolution of non-immune histological injury and its clinical relevance in adult-sized kidney grafts in pediatric recipients. Am J Transplant 2007;7:25042514. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  29. Franz M, Regele H, Schmaldienst S, Stummvoll HK, Horl WH, Pohanka E. Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: Advantage of FK506 therapy? Transplantation 1998;66:12581262. Prejsť na PubMed...
  30. Ponticelli C. De novo thrombotic microangiopathy. An underrated complication of renal transplantation. Clin Nephrol 2007;67:335 340. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  31. Oyen O, Strom EH, Midtvedt K, Bentdal O, Hartmann A, Bergan S, Pfeffer P, Brekke IB. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/ hemolytic uremic syndrome. Am J Transplant 2006;6:412418. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  32. Bren A, Pajek J, Grego K, Buturovic J, Ponikvar R, Lindic J, Knap B, Vizjak A, Ferluga D, Kandus A. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy. Transplant Proc 2005;37:18891891. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  33. Ashman N, Chapagain A, Dobbie H, Raftery MJ, Sheaff MT, Yaqoob MM. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am J Transplant 2009;9:424427. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  34. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol 1993;17:6068. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  35. Williams D, Haragsim L. Calcineurin nephrotoxicity. Adv Chronic Kidney Dis 2006;13:4755. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  36. Nieves-Cintron M, Amberg GC, Nichols CB, Molkentin JD, Santana LF. Activation of NFATc3 down-regulates the beta1 subunit of large conductance, calcium-activated K+ channels in arterial smooth muscle and contributes to hypertension. J Biol Chem 2007;282:32313240. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  37. Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998;49:356363.
  38. Collins BS, Davis CL, Marsh CL, McVicar JP, Perkins JD, Alpers CE. Reversible cyclosporine arteriolopathy. Transplantation 1992;54:732734. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  39. Djamali A. Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts. Am J Physiol Renal Physiol 2007;293:F445F455. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  40. Shihab FS, Yi H, Bennett WM, Andoh TF. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 2000;58:11741185. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  41. Pichler RH, Franceschini N, Young BA, Hugo C, Andoh TF, Burdmann EA, Shankland SJ, Alpers CE, Bennett WM, Couser WG. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995;6:11861196.
  42. Feldman G, Kiely B, Martin N, Ryan G, McMorrow T, Ryan MP. Role for TGF-beta in cyclosporine-induced modulation of renal epithelial barrier function. J Am Soc Nephrol 2007;18:16621671. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  43. Hertig A, Anglicheau D, Verine J, Pallet N, Touzot M, Ancel PY, Mesnard L, Brousse N, Baugey E, Glotz D, Legendre C, Rondeau E, Xu-Dubois YC. Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 2008;19:15841591. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  44. Viklický O, Matl I, Voska L, Böhmová R, Jarešová M, Lácha J, Lodererová A, Stříž I, Teplan V, Vítko S. TGF-beta1 expression and chronic allograft nephropathy in protocol kidney graft biopsy. Physiol Res 2003;52:353360.
  45. Ling H, Li X, Jha S, Wang W, Karetskaya L, Pratt B, Ledbetter S. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 2003;14:377388. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  46. Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 2008;19:1459 1462. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  47. Nankivell B, Richard J, Borrows R, Fung CL-S, OConnell PJ, Allen R, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:23262333. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  48. Nankivell BJ, Borrows RJ, Fung C L-S, OConnell PJ, Chapman JR, Allen RD. Calcineurin-inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004;78:557 565. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  49. Woolley AC, Rosenberg ME, Burke BA, Nath KA. De novo focal glomerulosclerosis after kidney transplantation. Am J Med 1988;84:310314. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  50. Heering P, Grabensee B. Influence of ciclosporin A on renal tubular function after kidney transplantation. Nephron 1991;59:6670. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  51. Lea JP, Sands JM, McMahon SJ, Tumlin JA. Evidence that the inhibition of Na+/K(+)-ATPase activity by FK506 involves calcineurin. Kidney Int 1994;46:647652. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  52. Younes-Ibrahim M, Barnese M, Burth P, Castro-Faria MV. Inhibition of purified human kidney Na+,K+-ATPase by cyclosporine A: A possible mechanism for drug human nephrotoxicity. Ann N Y Acad Sci 2003;986:633635. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  53. Heering PJ, Klein-Vehne N, Fehsel K. Decreased mineralocorticoid receptor expression in blood cells of kidney transplant recipients undergoing immunosuppressive treatment: Cost efficient determination by quantitative PCR. J Clin Pathol 2004;57:3336. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  54. Chang CT, Hung CC, Tian YC, Yang CW, Wu MS. Ciclosporin reduces paracellin-1 expression and magnesium transport in thick ascending limb cells. Nephrol Dial Transplant 2007;22:10331040. Prejsť k pôvodnému zdroju...
  55. Alexander RT, Hoenderop JG, Bindels RJ. Molecular determinants of magnesium homeostasis: Insights from human disease. J Am Soc Nephrol 2008;19:14511458. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  56. Miura K, Nakatani T, Asai T, Yamanaka S, Tamada S, Tashiro K, Kim S, Okamura M, Iwao H. Role of hypomagnesemia in chronic cyclosporine nephropathy. Transplantation 2002;73:340347. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  57. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000;11:974979.
  58. Woywodt A, Bahlmann FH, De Groot K, Haller H, Haubitz M. Circulating endothelial cells: life, death, detachment and repair of the endothelial cell layer. Nephrol Dial Transplant 2002;17:1728 1730. Prejsť k pôvodnému zdroju...
  59. Koo DD, Roberts IS, Quiroga I, Procter J, Barnardo MC, Sutton M, Cerundolo L, Davies DR, Friend PJ, Morris PJ, Fuggle SV. C4d deposition in early renal allograft protocol biopsies. Transplantation 2004;78:398403. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  60. Krejčí K, Zadražil J, Tichý T, Al-Jabry S, Horčička V, Štrebl P, Bachleda P. Sonographic findings in borderline changes and subclinical acute renal allograft rejection. Eur J Radiol 2009;71:288 295. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  61. Solez K, Vincenti F, Filo R. Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus ciclosporine. Transplantation 1998;66:17361740. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  62. Klein IH, Abrahams A, van ET, Hene RJ, Koomans HA, Ligtenberg G. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002;73:732736. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  63. Jain S, Bicknell G, Nicholson ML. Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury. Br J Surg 2000;87:15631568. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  64. OGrady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: The TMC randomised controlled trial. Lancet 2002;360:1119 1125. Prejsť k pôvodnému zdroju...
  65. Rowshani AT, Scholten EM, Bemelman F, Eikmans M, Idu M, Roos-van Groningen MC, Surachno JS, Mallat MJ, Paul LC, de Fijter JW, Bajema IM, ten Berge I, Florquin S. No difference in degree of interstitial Sirius redstained area in serial biopsies from area under concentration-over-time curvesguided cyclosporine versus tacrolimus-treated renal transplant recipients at one zdar. J Am Soc Nephrol 2006;17:305312. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  66. Vural A, Yilmaz MI, Caglar K, Aydin A, Sonmez A, Eyileten T, Acikel C, Gulec B, Kozak O, Oner K. Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. Am J Nephrol 2005; 25:250255. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  67. Zadražil J, Štrebl P, Krejčí K, Horčička V, Horák P, Dostálová J, Zdařilová A, Kajabová M, Schneidera P. Effect of different calcineurin inhibitors on AOPP and TAS after kidney transplantation. Clin Biochem 2010;43:559565. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  68. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005;331:810814. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  69. Zadrazil J, Krejci K, Al Jabry S, Horcicka V Jr, Tichy T, Hrabalova M, Bachleda P. Protocol biopsy and subclinical rejection in patients after kidney transplantation treated by tacrolimus (Prograf). Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003;147:193196. Prejsť k pôvodnému zdroju...
  70. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nathan B, Gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:25622575. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  71. Zadrazil J, Horak P, Zahalkova J, Strebl P, Horcicka V, Krejci K, Bachleda P, Dedochova J, Valkovsky I. Improvement of cardiovascular risk factors and cosmetic side effects in kidney transplant recipients after conversion to tacrolimus. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009;153:6773. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  72. Vincenti F, Friman S, Scheuermann E, Rostaing L, Nenesen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007;7:15061514. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  73. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:22112221. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  74. Oellerich M, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: Recent developments. Ther Drug Monit 2006;28:720725. Prejsť k pôvodnému zdroju...
  75. Canadian Neoral Renal Transplantation Study Group: Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation 2001;72:10241032.
  76. International Neoral Renal Transplantation Study Group: Cyclosporine microemulsion (Neoral) absorption profilig and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002;2:148156. Prejsť k pôvodnému zdroju...
  77. Krejčí K, Tichý T, Hrubý M, Horák P, Ciferská H, Horčička V, Štrebl P, Al-Jabry S, Bachleda P, Zadražil J. Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damage. Transpl Int 2010;23:364373. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  78. Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999;62:2531. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  79. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248260. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  80. Min DI, Ellingrod VL. Association of the CYP3A4*1B 5 flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2003;25:305309. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  81. Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, van der Werf M, Weimar W, Mathot RA. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in theMDR-1,CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004;76:545556. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  82. Rivory LP, Qin H, Clarke SJ, Eris J, Duggin G, Ray E, Trent RJ, Bishop JF. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance. Eur J Clin Pharmacol 2000;56:395398. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  83. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001;47:10481052.
  84. Min DI, Ellingrod VL, Marsh S, McLeod H. CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2004;26:524528. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  85. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14:147154. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  86. Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, Eap CB. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit 2008;30:689699. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  87. Singh R, Srivastava A, Kapoor R, K Sharma R, D Mittal R. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmied Arch Pharmacol 2009;380:169177. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  88. Kreutz R, Zürcher H, Kain S, Martus P, Offermann G, Beige J. The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 2004;14:665671. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  89. Zhao Y, Song M, Guan D, Bi S, Meng J, Li Q, Wang W. Genetic polymorphisms of CYP3A5 genes and concentration the cyclosporine and tacrolimus. Transplant Proc 2005;37:178181. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  90. Coto E, Tavira B. Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 2009;88(3 Suppl):S6267. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  91. Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Büchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004;75:422433. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  92. Foote CJ, Greer W, Kiberd B, Fraser A, Lawen J, Nashan B, Belitsky P. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantation 2007;83:13801384. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  93. Mai I, Störmer E, Goldammer M, Johne A, Krüger H, Budde K, Roots I. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol 2003;43:11011107. Prejsť k pôvodnému zdroju...
  94. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74:245254. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  95. Op den Buijsch RA, Christiaans MH, Stolk LM, de Vries JE, Cheung CY, Undre NA, van Hooff JP, van Dieijen-Visser MP, Bekers O. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette Bi (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 2007;21:427435. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  96. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007;81:228234. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  97. Jun KR, Lee W, Jang MS, Chun S, Song GW, Park KT, Lee SG, Han DJ, Kang C, Cho DY, Kim JQ, Min WK. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation 2009;87:12251231. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  98. Akbas SH, Bilgen T, Keser I, Tuncer M, Yucetin L, Tosun O, Gultekin M, Luleci G. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant Proc 2006;38:12901292. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  99. Li D, Gui R, Li J, Huang Z, Nie X. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. Transplant Proc 2006;38:28502852. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  100. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004;78:11821187. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  101. Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, Habuchi T. Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 2005; 37:17301732. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  102. Halloran PF, Helms LM, Kung L, Noujaim J. The tempoval profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999;68:13561361. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  103. Iwasaki K, Shiraga T, Matsuda H, Teramura Y, Kawamura A, Hata T, Ninomiya S, Esumi Y. Absorption, distribution, metabolism and excretion of tacrolimus (FK506) in the rat. Drug Metab Pharmacokinet 1998;13:259265. Prejsť k pôvodnému zdroju...
  104. Podder H, Stepkowski SM, Napoli KL, Clark J, Verani RR, Chou TC, Kahan BD. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001;12:10591071.
  105. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993;268:60776080.
  106. del Moral RG, Andujar M, Ramirez C, Gomez-Morales M, Masseroli M, Aguilar M, Olmo A, Arrebola F, Guillen M, Garcia- Chicano MJ, Nogales FF, OValle F. Chronic cyklosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits. Am J Pathol 1997;151:1705 1714. Prejsť na PubMed...
  107. Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, Ackermann H, Seidl C, Hocher B, Zanger UM, Geiger H, Eichelbaum M, Schwab M. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005;16:15011511. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  108. Roby KA, Shaw LM. Effects of cyclosporine and its metabolites in the isolated perfused rat kidney. J Am Soc Nephrol 1993;4:168 177. Prejsť na PubMed...
  109. Copeland KR, Thliveris JA, Yatscoff RW. Toxicity of cyclosporine metabolites. Ther Drug Monit 1990;12:525532. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  110. Christians U, Kohlhaw K, Budniak J, Bleck JS, Schottmann R, Schlitt HJ, Almeida VM, Deters M, Wonigeit K, Pichlmayr R. Cyclosporine metabolite pattern in blood and urine of liver graft recipients. I. Association of cyclosporine metabolites with nephrotoxicity. Eur J Clin Pharmacol 1991;41:285290. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  111. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383391. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  112. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 singlenucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007;82:711725. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  113. Schmitt R, Cantley LG. The impact of aging on kidney repair. Am J Physiol Renal Physiol 2008;294:F1265F1272. Prejsť k pôvodnému zdroju...
  114. Jennings P, Koppelstaetter C, Aydin S, Abberger T, Wolf AM, Mayer G, Pfaller W. Cyclosporine A induces senescence in renal tubular epithelial cells. Am J Physiol Renal Physiol 2007;293:F831F838. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  115. Altman RD, Perez GO, Sfakianakis GN. Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis. Am J Med 1992;93:396402. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  116. Soubhia RM, Mendes GE, Mendonca FZ, Baptista MA, Cipullo JP, Burdmann EA. Tacrolimus and nonsteroidal anti-inflammatory drugs: An association to be avoided. Am J Nephrol 2005;25:327 334. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  117. van de Wetering J, Weimar CH, Balk AH, Roodnat JI, Holweg CT, Baan CC, van Domburg RT, Weimar W. The impact of transforming growth factor-beta1 gene polymorphism on end-stage renal failure after heart transplantation. Transplantation 2006;82:1744 1748. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  118. Broekroelofs J, Stegeman CA, Navis G, Tegzess AM, De ZD, De Jong PE. Risk factors for long-term renal survival after renal transplantation: A role for angiotensin-converting enzyme (insertion/ deletion) polymorphism? J Am Soc Nephrol 1998;9:20752081.
  119. Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: Objectives and interim result. Clin J Am Soc Nephrol 2008;3:S101S116. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  120. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor- sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008;22:115. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  121. Rahn KH, Barenbrock M, Fritschka E, Heinecke A, Lippert J, Schroeder K, Hauser I, Wagner K, Neumayer HH. Effect of nitrendipine on renal function in renal-transplant patiens treated with cyclosporin: A randomised trial. Lancet 1999;354:14151420. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  122. Kuypers DR, Neumayer H-H, Fritsche L, Budde K, Rodicio J, Vanrenterghem Y, Lacidipine Study Group. Calcium channel blockade and preservation of renal graft function in cyclosporinetreated recipients: A prospective randomized placebo-controlled 2-year study. Transplantation 2004;78:12041211. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  123. Morales JM, Rodriguez-Paternina E, Araque A, Andres A, Hernandez E, Ruilope LM, Rodicio JL. Long-term protective effect of a calcium antagonist on renal function in hypertensive renal transplant patients on cyclosporine therapy: A 5-year prospective randomized study. Transplant Proc 1994;26:25982599.
  124. Hannedouche TP, Natov S, Boitard C, Lacour B, Grunfeld JP. Angiotensin converting enzyme inhibition and chronic cyclosporine- induced renal dysfunction in type 1 diabetes. Nephrol Dial Transplant 1996;11:673678. Prejsť k pôvodnému zdroju...
  125. Campistol JM, Inigo P, Jimenez W, Lario S, Clesca PH, Oppenheimer F, Rivera F. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999;56:714719. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  126. Inigo P, Campistol JM, Lario S, Piera C, Campos B, Bescos M, Oppenheimer F, Rivera F. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001;12:822827.
  127. Asai T, Nakatani T, Tamada S, Kuwabara N, Yamanaka S, Tashiro K, Nakao T, Komiya T, Okamura M, Kim S, Iwao H, Miura K. Activation of transcription factors AP-1 and NF-kappaB in chronic cyclosporine A nephrotoxicity: Role in beneficial effects of magnesium supplementation. Transplantation 2003;75:10401044. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  128. Li C, Sun BK, Lim SW, Song JC, Kang SW, Kim YS, Kang DH, Cha JH, Kim J, Yang CW. Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy. Transplantation 2005; 79:15221529. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  129. Tariq M, Morais C, Sobki S, Al Sulaiman M, Al Khader A. N-acetylcysteine attenuates cyclosporin-induced nephrotoxicity in rats. Nephrol Dial Transplant 1999;14:923929. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  130. Jenkins JK, Huang H, Ndebele K, Salahudeen AK. Vitamin E inhibits renal mRNA expression of COX II, HO I, TGFbeta, and osteopontin in the rat model of cyclosporine nephrotoxicity. Transplantation 2001;71:331334. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  131. Lessio C, de Assuncao SF, Gloria MA, Di Tommaso AB, Gori MM, Di Marco GS, Schor N, Higa EM. Cyclosporine A and NAC on the inducible nitric oxide synthase expression and nitric oxide synthesis in rat renal artery cultured cells. Kidney Int 2005;68:25082516. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  132. Galletti P, Di Gennaro CNI, Migliardi V, Indaco S, Della RF, Manna C, Chiodini P, Capasso G, Zappia V. Diverse effects of natural antioxidants on cyclosporin cytotoxicity in rat renal tubular cells. Nephrol Dial Transplant 2005;20:15511558. Prejsť k pôvodnému zdroju... Prejsť na PubMed...

Späť na obsah